Loading...

KalVista Pharmaceuticals

DB:4XC1
Snowflake Description

Excellent balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
4XC1
DB
$440M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The last earnings update was 38 days ago. More info.


Add to Portfolio Compare Print
  • KalVista Pharmaceuticals has significant price volatility in the past 3 months.
4XC1 Share Price and Events
7 Day Returns
-4.4%
DB:4XC1
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
198.6%
DB:4XC1
-10.2%
DE Biotechs
-6%
DE Market
4XC1 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
KalVista Pharmaceuticals (4XC1) -4.4% -11.1% 53.8% 198.6% - -
DE Biotechs -2.4% 3.2% -7.7% -10.2% 51.2% 10.1%
DE Market 1.8% 4.6% 7.4% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • 4XC1 outperformed the Biotechs industry which returned -10.2% over the past year.
  • 4XC1 outperformed the Market in Germany which returned -6% over the past year.
Price Volatility
4XC1
Industry
5yr Volatility vs Market
Related Companies

Value

 Is KalVista Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for KalVista Pharmaceuticals. This is due to cash flow or dividend data being unavailable. The share price is €22.275.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for KalVista Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are KalVista Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:4XC1 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-01-31) in USD $-0.96
NasdaqGM:KALV Share Price ** NasdaqGM (2019-04-18) in USD $25.5
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of KalVista Pharmaceuticals.

DB:4XC1 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:KALV Share Price ÷ EPS (both in USD)

= 25.5 ÷ -0.96

-26.55x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • KalVista Pharmaceuticals is loss making, we can't compare its value to the Europe Biotechs industry average.
  • KalVista Pharmaceuticals is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does KalVista Pharmaceuticals's expected growth come at a high price?
Raw Data
DB:4XC1 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -26.55x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
-59.7%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for KalVista Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on KalVista Pharmaceuticals's assets?
Raw Data
DB:4XC1 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-01-31) in USD $6.03
NasdaqGM:KALV Share Price * NasdaqGM (2019-04-18) in USD $25.5
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:4XC1 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:KALV Share Price ÷ Book Value per Share (both in USD)

= 25.5 ÷ 6.03

4.23x

* Primary Listing of KalVista Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • KalVista Pharmaceuticals is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess KalVista Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. KalVista Pharmaceuticals has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is KalVista Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-59.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is KalVista Pharmaceuticals expected to grow at an attractive rate?
  • Unable to compare KalVista Pharmaceuticals's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare KalVista Pharmaceuticals's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • KalVista Pharmaceuticals's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:4XC1 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:4XC1 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts -59.7%
DB:4XC1 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts 44.7%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:4XC1 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:4XC1 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-04-30 151 -30 1
2022-04-30 26 -68 1
2021-04-30 8 -66 -75 2
2020-04-30 33 -47 -64 4
2019-04-30 17 -27 -30 3
DB:4XC1 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-01-31 18 -32 -13
2018-10-31 16 7 -14
2018-07-31 12 9 -16
2018-04-30 8 11 -16
2018-01-31 4 14 -19
2017-10-31 2 -26 -22
2017-07-31 1 -23 -21
2017-04-30 2 -24 -21
2017-01-31 2 -23 -23
2016-10-31 2 -15 -18
2016-07-31 2 -15 -18
2016-04-30 2 -13 -15

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • KalVista Pharmaceuticals is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • KalVista Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:4XC1 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from KalVista Pharmaceuticals Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:4XC1 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-04-30
2022-04-30
2021-04-30 -4.28 -4.28 -4.28 1.00
2020-04-30 -4.21 -4.21 -4.21 1.00
2019-04-30 -2.11 -2.11 -2.11 1.00
DB:4XC1 Past Financials Data
Date (Data in USD Millions) EPS *
2019-01-31 -0.96
2018-10-31 -1.20
2018-07-31 -1.50
2018-04-30 -1.53
2018-01-31 -1.93
2017-10-31 -2.38
2017-07-31 -3.07
2017-04-30 -4.47
2017-01-31 -9.43
2016-10-31 -7.40
2016-07-31 -48.84
2016-04-30 -26.17

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if KalVista Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess KalVista Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
KalVista Pharmaceuticals has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has KalVista Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare KalVista Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • KalVista Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare KalVista Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare KalVista Pharmaceuticals's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
KalVista Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from KalVista Pharmaceuticals Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:4XC1 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-01-31 18.04 -12.95 9.84
2018-10-31 16.48 -14.23 9.07
2018-07-31 12.02 -15.91 9.16
2018-04-30 8.39 -15.81 8.86
2018-01-31 3.67 -19.35 2.71
2017-10-31 1.59 -21.95 5.61
2017-07-31 0.63 -21.23 4.15
2017-04-30 1.50 -20.78 4.78
2017-01-31 1.67 -22.80 10.10
2016-10-31 1.77 -18.04 5.61
2016-07-31 2.27 -17.51 4.97
2016-04-30 2.13 -15.48 2.65
2015-04-30 1.80 -9.20 1.61

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if KalVista Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if KalVista Pharmaceuticals has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if KalVista Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess KalVista Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
KalVista Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is KalVista Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up KalVista Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • KalVista Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • KalVista Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of KalVista Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 1138.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from KalVista Pharmaceuticals Company Filings, last reported 2 months ago.

DB:4XC1 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-01-31 104.03 0.11 111.15
2018-10-31 106.95 0.16 121.12
2018-07-31 26.25 0.21 48.07
2018-04-30 27.25 0.28 51.06
2018-01-31 28.57 0.34 58.68
2017-10-31 31.08 0.37 28.13
2017-07-31 26.73 0.42 26.46
2017-04-30 31.33 0.00 30.95
2017-01-31 34.85 0.00 33.50
2016-10-31 11.84 0.00 10.68
2016-07-31 16.21 0.00 15.63
2016-04-30 21.50 0.00 21.76
2015-04-30 2.05 0.00 2.53
  • KalVista Pharmaceuticals's level of debt (0.1%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if KalVista Pharmaceuticals's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • KalVista Pharmaceuticals has sufficient cash runway for more than 3 years based on current free cash flow.
  • KalVista Pharmaceuticals has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -31.3% each year.
X
Financial health checks
We assess KalVista Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. KalVista Pharmaceuticals has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is KalVista Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from KalVista Pharmaceuticals dividends.
If you bought €2,000 of KalVista Pharmaceuticals shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate KalVista Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate KalVista Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:4XC1 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:4XC1 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-04-30
2022-04-30
2021-04-30
2020-04-30
2019-04-30

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as KalVista Pharmaceuticals has not reported any payouts.
  • Unable to verify if KalVista Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of KalVista Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as KalVista Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess KalVista Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can KalVista Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. KalVista Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of KalVista Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Andy Crockett
COMPENSATION $605,326
AGE 43
TENURE AS CEO 2.4 years
CEO Bio

Mr. Thomas Andrew Crockett, also known as Andy, M.B.A., has been Chief Executive Officer and Director of KalVista Pharmaceuticals, Inc. since November 21, 2016. Mr. Crockett is the Founder of KalVista Pharmaceuticals Ltd. and also served as its Chief Executive Officer. Mr. Crockett has been the Chief Executive Officer of Vantia Ltd. since June 2010. He served as Vice President of business development of Vantia Ltd. from 2009 to June 2010. Mr. Crockett served as Vice President of Business Development of ZARS Pharma, Inc. since June 2005. Mr. Crockett served as Director of S-Caine Projects and Business Development of ZARS Pharma, Inc. Mr. Crockett joined Zars in August 1999. He held various senior management positions including chief executive, vice president of business development and director or clinical and regulatory affairs in biotech and specialty pharmaceutical companies in the United States and United Kingdom. During his career he has identified, negotiated and executed strategic corporate transactions on a global basis, including merger and acquisitions, national and international product licences, IP and technology licences and R&D alliances. He worked in the engineering department and managed the manufacturing activities at Microject, a drug delivery technology company, from June 1997 to June 1999. He served as a Director at KalVista Pharmaceuticals Ltd. He serves as a Director of Vantia Ltd. Mr. Crockett holds a B.A. from the University of Utah. Mr. Crockett has studied at Harvard Business School and also holds an MBA from The Wharton School, University of Pennsylvania, with a major in finance.

CEO Compensation
  • Insufficient data for Andy to compare compensation growth.
  • Insufficient data for Andy to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the KalVista Pharmaceuticals management team in years:

2.4
Average Tenure
53
Average Age
  • The tenure for the KalVista Pharmaceuticals management team is about average.
Management Team

Andy Crockett

TITLE
CEO & Director
COMPENSATION
$605K
AGE
43
TENURE
2.4 yrs

Ben Palleiko

TITLE
Chief Business Officer & CFO
COMPENSATION
$481K
AGE
52
TENURE
2.7 yrs

Andreas Maetzel

TITLE
Senior Vice President of Medical
COMPENSATION
$417K
AGE
55
TENURE
2.1 yrs

John McKune

TITLE
Vice President of Finance
COMPENSATION
$516K
AGE
42

Ed Feener

TITLE
Chief Scientific Officer
AGE
58
TENURE
2.4 yrs

Rachel Morten

TITLE
Head of Regulatory Affairs and QA

Chris Yea

TITLE
Chief Development Officer
AGE
54
TENURE
2.4 yrs

Stephen Donnelly

TITLE
Director of Finance and Company Secretary
Board of Directors Tenure

Average tenure and age of the KalVista Pharmaceuticals board of directors in years:

2.4
Average Tenure
59
Average Age
  • The average tenure for the KalVista Pharmaceuticals board of directors is less than 3 years, this suggests a new board.
Board of Directors

Rich Aldrich

TITLE
Chairman of the Board
COMPENSATION
$94K
AGE
64
TENURE
2.4 yrs

Andy Crockett

TITLE
CEO & Director
COMPENSATION
$605K
AGE
43
TENURE
2.4 yrs

Ed Unkart

TITLE
Director
COMPENSATION
$118K
AGE
68
TENURE
4.3 yrs

Albert Cha

TITLE
Director
COMPENSATION
$113K
AGE
46
TENURE
2.4 yrs

Tomas Kiselak

TITLE
Board Observer
TENURE
3.8 yrs

Bong Koh

TITLE
Board Observer
AGE
45
TENURE
3.8 yrs

Arnie Oronsky

TITLE
Director
COMPENSATION
$88K
AGE
79
TENURE
2.4 yrs

Brian J. Pereira

TITLE
Director
AGE
59
TENURE
0.2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
15. Apr 19 Buy RA Capital Management, LLC Company 05. Apr 19 11. Apr 19 482,500 €26.23 €12,068,435
10. Apr 19 Sell SV Health Investors, LLC Company 08. Apr 19 10. Apr 19 -50,000 €26.19 €-1,296,901
02. Apr 19 Sell SV Health Investors, LLC Company 29. Mar 19 02. Apr 19 -97,074 €25.71 €-2,432,210
28. Mar 19 Sell SV Health Investors, LLC Company 26. Mar 19 28. Mar 19 -124,675 €26.46 €-3,204,065
20. Mar 19 Sell VR Adviser, LLC Company 18. Mar 19 18. Mar 19 -500,000 €25.36 €-12,681,625
20. Mar 19 Sell SV Health Investors, LLC Company 18. Mar 19 18. Mar 19 -262,470 €23.55 €-6,182,413
06. Mar 19 Sell SV Health Investors, LLC Company 04. Mar 19 05. Mar 19 -75,710 €20.39 €-1,538,551
21. Feb 19 Sell SV Health Investors, LLC Company 19. Feb 19 21. Feb 19 -214,198 €18.29 €-3,883,314
07. Jan 19 Sell SV Health Investors, LLC Company 03. Jan 19 07. Jan 19 -4,299 €17.80 €-75,936
03. Jan 19 Sell SV Health Investors, LLC Company 28. Dec 18 02. Jan 19 -29,352 €17.64 €-517,126
21. Dec 18 Sell SV Health Investors, LLC Company 19. Dec 18 19. Dec 18 -2,136 €17.52 €-37,422
12. Sep 18 Buy InterWest Partners LLC Company 10. Sep 18 10. Sep 18 58,824 €14.65 €861,507
X
Management checks
We assess KalVista Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. KalVista Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company’s product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, an intravitreally administered plasma kallikrein inhibitor that is in Phase II clinical trials for the treatment of DME; and KVD900, a potent inhibitor of plasma kallikrein, which is in Phase I clinical trial for treating HAE. The company is headquartered in Cambridge, Massachusetts.

Details
Name: KalVista Pharmaceuticals, Inc.
4XC1
Exchange: DB
Founded: 2011
$391,076,717
17,247,348
Website: http://www.kalvista.com
Address: KalVista Pharmaceuticals, Inc.
55 Cambridge Parkway,
Suite 901 East,
Cambridge,
Massachusetts, 02142,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM KALV New Ordinary Shares Nasdaq Global Market US USD 23. Nov 2016
DB 4XC1 New Ordinary Shares Deutsche Boerse AG DE EUR 23. Nov 2016
Number of employees
Current staff
Staff numbers
33
KalVista Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/21 21:55
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/02
Last earnings filing: 2019/03/14
Last earnings reported: 2019/01/31
Last annual earnings reported: 2018/04/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.